Oncopeptides announces net sales for Q2 2025
July 9, 2025 – Oncopeptides releases this information ahead of the interim report for the second quarter 2025 as net sales are determined by the company to be higher than both the company´s projections and assumed market expectations.
Pepaxti included in European Guidelines for the treatment of multiple myeloma
July 8, 2025 – Oncopeptides today announced that its drug Pepaxti has been recommended in new clinical practice guidelines from EHA-EMN* for patients with relapsed, refractory multiple myeloma.